MUC1 inhibition leads to decrease in PD-L1 levels via upregulation of miRNAs

MUC1-C drives MYC in multiple myeloma

(2016) Ashujit Tagde et al.   BLOOD

Inhibition of MUC1-C Suppresses MYC Expression and Attenuates Malignant Growth in KRAS Mutant Lung Adenocarcinomas

(2016) Audrey Bouillez et al.   CANCER RESEARCH

Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study

(2016) David F. McDermott et al.   JOURNAL OF CLINICAL ONCOLOGY

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

(2016) Louis Fehrenbacher et al.   LANCET

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

(2016) Jonathan E Rosenberg et al.   LANCET

Loss of oncogenic miR-155 in tumor cells promotes tumor growth by enhancing C/EBP-β-mediated MDSC infiltration

(2016) Sinae Kim et al.   Oncotarget

Impaired expression of DICER and some microRNAs in HBZ expressing cells from acute adult T-cell leukemia patients

(2016) Hélène Gazon et al.   Oncotarget

ERK/c-Jun Recruits Tet1 to Induce Zta Expression and Epstein-Barr Virus Reactivation through DNA Demethylation

(2016) Wei Zhang et al.   Scientific Reports

c-Jun N-terminal Kinase (JNK) Signaling as a Therapeutic Target for Alzheimer’s Disease

(2016) Ramon Yarza et al.   Frontiers in Pharmacology

MUC1 upregulation promotes immune resistance in tumor cells undergoing brachyury-mediated epithelial-mesenchymal transition

(2016) Justin M. David et al.   OncoImmunology

Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia

(2015) Xi Wang et al.   CELLULAR SIGNALLING

RNA Binding Proteins in the miRNA Pathway

(2015) Patrick Connerty et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

The immunosuppressive ligands PD-L1 and CD200 are linked in AML T-cell immunosuppression: identification of a new immunotherapeutic synapse

(2015) S J Coles et al.   LEUKEMIA

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

(2015) Stephen M. Ansell et al.   NEW ENGLAND JOURNAL OF MEDICINE

MUC1-C activates the TAK1 inflammatory pathway in colon cancer

(2015) H Takahashi et al.   ONCOGENE

Mucin1 promotes the migration and invasion of hepatocellular carcinoma cells via JNK-mediated phosphorylation of Smad2 at the C-terminal and linker regions

(2015) Juan Wang et al.   Oncotarget

Peripheral myeloid-derived suppressor and T regulatory PD-1 positive cells predict response to neoadjuvant short-course radiotherapy in rectal cancer patients

(2015) Maria Napolitano et al.   Oncotarget

Mucin1 shifts Smad3 signaling from the tumor-suppressive pSmad3C/p21WAF1 pathway to the oncogenic pSmad3L/c-Myc pathway by activating JNK in human hepatocellular carcinoma cells

(2015) Qiongshu Li et al.   Oncotarget

PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation

(2014) Muhammad Zaeem Noman et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Identification of nuclear hormone receptor pathways causing insulin resistance by transcriptional and epigenomic analysis

(2014) Sona Kang et al.   NATURE CELL BIOLOGY

MicroRNA-34a: a potential therapeutic target in human cancer

(2014) X J Li et al.   Cell Death & Disease

Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression

(2014) Limo Chen et al.   Nature Communications

Anti-programmed death receptor 1 immunotherapy in melanoma: rationale, evidence and clinical potential

(2014) Morganna Freeman-Keller et al.   Therapeutic Advances in Medical Oncology

MUC1-C oncoprotein promotes FLT3 receptor activation in acute myeloid leukemia cells

(2013) S. Liu et al.   BLOOD

MUC1 Is a Potential Target for the Treatment of Acute Myeloid Leukemia Stem Cells

(2013) D. Stroopinsky et al.   CANCER RESEARCH

MUC1-C Oncoprotein Activates ERK→C/EBPβ Signaling and Induction of Aldehyde Dehydrogenase 1A1 in Breast Cancer Cells

(2013) Maroof Alam et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Dicer Deficiency Reveals MicroRNAs Predicted to Control Gene Expression in the Developing Adrenal Cortex

(2013) Kenneth T. Krill et al.   MOLECULAR ENDOCRINOLOGY

Increased Level of Myeloid-Derived Suppressor Cells, Programmed Death Receptor Ligand 1/Programmed Death Receptor 1, and Soluble CD25 in Sokal High Risk Chronic Myeloid Leukemia

(2013) Lisa Christiansson et al.   PLoS One

Immune evasion in acute myeloid leukemia: current concepts and future directions

(2013) Ryan M Teague et al.   Journal for ImmunoTherapy of Cancer

Loss of Dicer expression is associated with breast cancer progression and recurrence

(2012) Sarkawt M. Khoshnaw et al.   BREAST CANCER RESEARCH AND TREATMENT

Radiation-Induced c-Jun Activation Depends on MEK1-ERK1/2 Signaling Pathway in Microglial Cells

(2012) Zhiyong Deng et al.   PLoS One

miRNAs regulate stem cell self-renewal and differentiation

(2012) Zuoren Yu et al.   Frontiers in Genetics

MUC1-C oncoprotein suppresses reactive oxygen species-induced terminal differentiation of acute myelogenous leukemia cells

(2011) L. Yin et al.   BLOOD

Inhibition of the MUC1-C oncoprotein induces multiple myeloma cell death by down-regulating TIGAR expression and depleting NADPH

(2011) L. Yin et al.   BLOOD

Dicer-Mediated Upregulation of BCRP Confers Tamoxifen Resistance in Human Breast Cancer Cells

(2011) J. Selever et al.   CLINICAL CANCER RESEARCH

A Monoclonal Antibody Against the Oncogenic Mucin 1 Cytoplasmic Domain

(2011) Govind Panchamoorthy et al.   HYBRIDOMA

PD-1 Blockade by CT-011, Anti-PD-1 Antibody, Enhances Ex Vivo T-cell Responses to Autologous Dendritic Cell/Myeloma Fusion Vaccine

(2011) Jacalyn Rosenblatt et al.   JOURNAL OF IMMUNOTHERAPY

MUC1-C Oncoprotein Promotes STAT3 Activation in an Autoinductive Regulatory Loop

(2011) R. Ahmad et al.   Science Signaling

Functional targeting of the MUC1 oncogene in human cancers

(2010) Donald W. Kufe   CANCER BIOLOGY & THERAPY

In acute myeloid leukemia, B7-H1 (PD-L1) protection of blasts from cytotoxic T cells is induced by TLR ligands and interferon-gamma and can be reversed using MEK inhibitors

(2010) Céline Berthon et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Generation of Tumor-specific T Lymphocytes Using Dendritic Cell/Tumor Fusions and Anti-CD3/CD28

(2010) Jacalyn Rosenblatt et al.   JOURNAL OF IMMUNOTHERAPY

Survival of Human Multiple Myeloma Cells Is Dependent on MUC1 C-Terminal Transmembrane Subunit Oncoprotein Function

(2010) L. Yin et al.   MOLECULAR PHARMACOLOGY

Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts

(2009) R. Le Dieu et al.   BLOOD

PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model

(2009) L. Zhang et al.   BLOOD

MUC1-C Oncoprotein Functions as a Direct Activator of the Nuclear Factor- B p65 Transcription Factor

(2009) R. Ahmad et al.   CANCER RESEARCH

Cooperativity of the MUC1 oncoprotein and STAT1 pathway in poor prognosis human breast cancer

(2009) N Khodarev et al.   ONCOGENE

The impact of microRNAs on protein output

(2008) Daehyun Baek et al.   NATURE